Slocum, Gordon & Co’s Moderna MRNA Stock Holding History

Slocum, Gordon & Co’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$210K	Buy	+3,000	New	+$155K	0.14%	64

Other funds holding MRNA

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

LSA

Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

TFCP

Twin Focus Capital Partners Boston, Massachusetts $983M AUM 37.07% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Slocum, Gordon & Co's MRNA Position: Q2 2026 in Review

Slocum, Gordon & Co opened a new position in Moderna (MRNA) in Q2 2026: 3,000 shares worth $210K. The stake represents 0.14% of the portfolio and ranks #64 among its holdings.

225 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Slocum, Gordon & Co held 3,000 shares of Moderna worth $210K as of Q2 2026.
Moderna was a new Slocum, Gordon & Co position in Q2 2026.
Moderna made up 0.14% of Slocum, Gordon & Co's portfolio in Q2 2026, its #64 holding.
225 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Slocum, Gordon & Co's 13F filing for Q2 2026, filed 23 Jul 2026.